Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Other research analysts also recently issued reports about the company. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of SYRS stock opened at $0.09 on Wednesday. Syros Pharmaceuticals has a 52-week low of $0.07 and a 52-week high of $7.60. The firm has a market capitalization of $2.28 million, a P/E ratio of -0.03 and a beta of 1.29. The stock has a 50 day moving average price of $0.19 and a 200 day moving average price of $0.99.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SYRS. Two Sigma Securities LLC purchased a new position in Syros Pharmaceuticals during the 4th quarter worth $25,000. GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals during the 3rd quarter worth $34,000. Finally, Exome Asset Management LLC grew its stake in Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares during the last quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.